[ad_1]
PD-1 x LAG-3 for EMB-02 and BCMA x CD3 for EMB-06 are currently undergoing clinical trials
EpimAb Biological TherapyA clinical-stage biotechnology company focused on bispecific antibodies, today announced EMB-02 (a bispecific antibody targeting PD-1 and LAG-3) in a phase 1/2 clinical trial for patients with advanced solid tumors Dosing for the first patient and a phase 1/2 clinical trial of EMB-06, which is a bispecific antibody against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) for Treatment of patients with relapsed and refractory multiple myeloma. The company also announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has approved its investigational new drug (IND) application for EMB-02.
“We are very pleased to continue to promote the momentum of our pipeline, in our two new clinical projects EMB-02 and EMB-06 Phase 1/2 trials to administer the first batch of patients, and EMB-02 IND Approved in China,” said Dr. Chengbin Wu, founder and CEO of EpimAb Biotherapeutics. “This validates the ability of our FIT-Ig platform to effectively generate new bispecific programs and its wide applicability to various goals. This is very important for us to continue to seek promising target combinations. We look forward to more Preclinical and clinical assets…
The full story on Benzinga.com
[ad_2]
Source link
